Current
Neuro-Oncology


Volume 21 Number 7
July 2019


Home > Disciplines > Publications > Current Neuro-Oncology > Volume 21, Year 2019 > Number 7, July


CONTENTS


GLIOMAS
HIGH-GRADE GLIOMAS
LOW-GRADE GLIOMAS

DIFFUSE ASTROCYTIC AND OLIGODENDROGLIAL TUMORS
GLIOBLASTOMA

EMBRYONAL TUMORS
MEDULLOBLASTOMA





GLIOMAS

.

Giovannini G, Pasini F, Orlandi N, Mirandola L, Meletti S.
Tumor-associated status epilepticus in patients with glioma: Clinical characteristics and outcomes.
Epilepsy Behav. 2019 Jul 9. pii: S1525-5050(19)30506-2. doi: 10.1016/j.yebeh.2019.06.014. [Epub ahead of print]
Source : Similar articles



HIGH-GRADE GLIOMAS


.

Fleischmann DF, Unterrainer M, Corradini S, Rottler M, Förster S, la Fougère C, Siepmann T, Schwaiger M, Bartenstein P, Belka C, Albert NL, Niyazi M.
Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
PLoS One. 2019 Jul 24;14(7):e0216111. doi: 10.1371/journal.pone.0216111. eCollection 2019.
Source . Similar articles



.

Villani V, Pace A, Vidiri A, Tanzilli A, Sperati F, Terrenato I, Mariantonia C, Casini B, Metro G, Maschio M, Tatiana K, Cognetti F, Fabi A.
Phase II study of weekly carboplatin in pretreated adult malignant gliomas.
J Neurooncol. 2019 Aug;144(1):211-216. doi: 10.1007/s11060-019-03223-x. Epub 2019 Jul 4.
Source . Similar articles



LOW-GRADE GLIOMAS


.

Zhao YY, Chen SH, Hao Z, Zhu HX, Xing ZL, Li MH.
A Nomogram for Predicting Individual Prognosis of Patients with Low-Grade Glioma.
World Neurosurg. 2019 Jul 15. pii: S1878-8750(19)31826-1. doi: 10.1016/j.wneu.2019.06.169. [Epub ahead of print]
Source . Similar articles



DIFFUSE ASTROCYTIC AND OLIGODENDROGLIAL TUMORS



GLIOBLASTOMA


.

Addeo R, Lamberti G, Simonetti G, Iodice P, Marinelli A, Montella L, Cappabianca S, Gaviani P, Caraglia M, Prete SD, Silvani A.
Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study.
CNS Oncol. 2019 Jul 10:CNS36. doi: 10.2217/cns-2019-0004. [Epub ahead of print]
Source . Similar articles



.

Du XJ, Li XM, Cai LB, Sun JC, Wang SY, Wang XC, Pang XL, Deng ML, Chen FF, Wang ZQ, Chen FR, Zhang HH, Wang HY, Piedra P, Chen ZP, Lin J, Wu SX.
Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial.
J Cancer. 2019 Jun 2;10(14):3214-3223. doi: 10.7150/jca.30123. eCollection 2019.
Source . Similar articles



.

Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, Giannini C, Buckner JC, Anastasiadis PZ, Schiff D.
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
Cancer. 2019 Jul 10. doi: 10.1002/cncr.32340. [Epub ahead of print]
Source . Similar articles



.

Kaley TJ, Panageas KS, Mellinghoff IK, Nolan C, Gavrilovic IT, DeAngelis LM, Abrey LE, Holland EC, Lassman AB.
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
J Neurooncol. 2019 Jul 19. doi: 10.1007/s11060-019-03243-7. [Epub ahead of print]
Source . Similar articles



.

Ricard JA, Cramer S, Charles R, Tommee CG, Le A, Bell WR, Chen C, Flanagan ME.
Infratentorial Glioblastoma Metastasis to Bone.
World Neurosurg. 2019 Jul 26. pii: S1878-8750(19)32048-0. doi: 10.1016/j.wneu.2019.07.142. [Epub ahead of print]
Source . Similar articles



.

Sharma M, Schilero C, Peereboom DM, Hobbs BP, Elson P, Stevens GHJ, McCrae K, Nixon AB, Ahluwalia MS.
Phase II study of Dovitinib in recurrent glioblastoma.
J Neurooncol. 2019 Jul 11. doi: 10.1007/s11060-019-03236-6. [Epub ahead of print]
Source . Similar articles



.

Tien AC, Li J, Bao X, DeRogatis A, Kim S, Mehta S, Sanai N.
A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.
Clin Cancer Res. 2019 Jul 8. pii: clincanres.0133.2019. doi: 10.1158/1078-0432.CCR-19-0133. [Epub ahead of print]
Source . Similar articles



.

Tini P, Nardone V, Pastina P, Marampon F, Sebaste L, Cerase A, Tombolini V, Pirtoli L, Mazzei MA.
Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival?
Clin Neurol Neurosurg. 2019 Sep;184:105445. doi: 10.1016/j.clineuro.2019.105445. Epub 2019 Jul 15.
Source . Similar articles



*.

Wang S, Yao F, Lu X, Li Q, Su Z, Lee JH, Wang C, Du L.
Temozolomide promotes immune escape of GBM cells via upregulating PD-L1.
Am J Cancer Res. 2019 Jun 1;9(6):1161-1171. eCollection 2019.
Source . Similar articles



.

Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, Markert J, LaRocca R, O'Rourke DM, Fink K, Kim L, Gruber M, Lesser GJ, Pan E, Kesari S, Muzikansky A, Pinilla C, Santos RG, Yu JS.
A Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell Vaccine ICT-107 In Newly Diagnosed Patients With Glioblastoma.
Clin Cancer Res. 2019 Jul 18. pii: clincanres.0261.2019. doi: 10.1158/1078-0432.CCR-19-0261. [Epub ahead of print]
Source . Similar articles



EMBRYONAL TUMORS



MEDULLOBLASTOMA


.

Kameda-Smith MM, Wang A, Abdulhadi N, Voth R, Sergeant A, Maharaj A, Bakhshinyan D, Adile AA, Pai AM, Ajani O, Yarascavitch B, Alyman MC, Duckworth J, Samaan MC, Farrokhyar F, Singh SK, Fleming A; Pediatric Brain Tumour Study Group.
Salvage Therapy for Childhood Medulloblastoma: A Single Center Experience.
Can J Neurol Sci. 2019 Jul;46(4):403-414. doi: 10.1017/cjn.2019.39.
Source . Similar articles



bottom